New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 1, 2013
09:17 EDTWAG, AIXG, MYGN, RH, MRK, PSTI, EDG, LXRX, BTNOn The Fly: Pre-market Movers
HIGHER: Merck (MRK), up 3% after announcing restructuring plans, including intent to cut about 20% of workforce by end 2015... Lexicon (LXRX), up 21% after achieving positive clinical trial results for potential diabetes drug... Edgen Group (EDG), up 57% after agreeing to be acquired by Sumitomo Corp. for $12.00 per share... Myriad Genetics (MYGN), up 11% after Piper Jaffray says should be bought on any weakness and stock upgraded at Ladenburg... Ballantyne Strong (BTN), up 6% after acquiring Convergent Media Systems... Pluristem (PSTI), up 5% after PLX cells demonstrate efficacy in preclinical study for GvHD. LOWER: Walgreens (WAG), down 0.5% after Q4 earnings report... Aixtron (AIXG), down 4% after downgrade at Canaccord... Restoration Hardware (RH), down 3% after holder CP Home files to sell about 4M shares.
News For MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 4, 2015
09:08 EDTLXRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTLXRXLexicon reports Q4 EPS (0c), consensus (3c)
Subscribe for More Information
March 3, 2015
15:20 EDTLXRXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include PetSmart (PETM), consensus $1.38... Trina Solar (TSL), consensus 13c... Lexicon Pharmaceuticals (LXRX), consensus (3c)... Abercrombie & Fitch (ANF), consensus $1.15... American Eagle Outfitters (AEO), consensus 34c... E. W. Scripps (SSP), consensus 40c.
05:30 EDTPSTIPluristem announce data showing PLX-R18 cells improve bone marrow transplant
Subscribe for More Information
March 2, 2015
07:20 EDTLXRXCowen to hold a conference
Subscribe for More Information
February 26, 2015
15:20 EDTMRKMerck says GARDASIL 9 recommended by CDC advisory committee
Subscribe for More Information
09:41 EDTMRKHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 25, 2015
08:08 EDTMRKMerck to present new data from IMPROVE-IT, TRA 2P studies
Subscribe for More Information
February 24, 2015
16:28 EDTMYGNMyriad Genetics board approves $200M increase in share buyback program
Subscribe for More Information
05:53 EDTAIXGAixtron sees 2015 revenue EUR 220M-EUR 250M
Subscribe for More Information
05:52 EDTAIXGAixtron reports Q4 EPS operating loss EUR 18.9M vs. EUR 12.6M last year
Reports Q4 sales EUR 58.0M vs. EUR 51.1M last year. Reports Q4 order intake EUR 39.9M vs. EUR 37.6M last year. The company said, "Results of fiscal year 2014 are in line with the previously published expectations, but continue to be unsatisfactory."
05:17 EDTMRKMerck collaborates with Medicines Patent Pool to expand Raltegravir access
Subscribe for More Information
February 23, 2015
16:34 EDTLXRXLexicon Chief Scientific Officer resigns
Lexicon Pharmaceuticals announced the resignation of Brian Zambrowicz, Ph.D., executive vice president and Chief Scientific Officer, to pursue another opportunity. Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition. In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development. Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.
08:27 EDTMRKNGM Biopharmaceuticals to hold a teleconference
NGM Biopharm discusses the strategic collaboration with Merck to discover, develop and commercialize novel biologic therapeutics on a teleconference to be held on February 23 at 9:30 am. Webcast Link
07:04 EDTMRKMerck, NGM Biopharmaceuticals announce multi-year collaboration
NGM Biopharmaceuticals and Merck announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201, which is being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis. NGM will lead the research and development of the existing preclinical candidates and have the autonomy to identify and pursue other discovery stage programs at its discretion. Merck will have the option to license all resulting NGM programs following human proof of concept trials. If Merck exercises this option, Merck will lead global product development and commercialization for the resulting products, if approved. Under the terms of the agreement, Merck will make an upfront payment to NGM of $94M and will purchase a 15 percent equity stake in NGM for $106M at a price per share that represents a 20% premium to NGMs most recent financing. Merck will commit up to $250M to fund all of NGMs efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States. Merck will have the option to extend the research agreement for two additional two-year terms.
February 20, 2015
10:01 EDTAIXGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:08 EDTMRKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
05:37 EDTAIXGAixtron upgraded to Hold from Sell at Societe Generale
February 19, 2015
12:50 EDTPSTIPluristem says NIH study of PLX-R18 statistically significant
Pluristem Therapeutics announced the results of a recently completed trial conducted by the U.S. National Institutes of Health to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation, the company said. It added, "The data also suggested that the treatment may potentially be able to shorten time to recovery."
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use